1,951 results on '"Haberkorn, Uwe"'
Search Results
2. Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
3. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
4. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer
5. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
6. Carbon Ion Beam Radiation Therapy as Part of a Trimodal Therapy for Non-small Cell Superior Sulcus Tumors: The INKA Study
7. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
8. Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
9. Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrier
10. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
11. 68Ga- or 18F-FAPI PET/CT—what it can and cannot
12. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
13. Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer
14. Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
15. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
16. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET
17. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
18. [68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
19. Deescalated225Ac-PSMA-617 Versus177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients
20. Diagnostic Potential of Supplemental Static and Dynamic68Ga-FAPI-46 PET for Primary18F-FDG–Negative Pulmonary Lesions
21. A Role of Non-FDG Tracers in Lung Cancer?
22. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
23. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies
24. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging
25. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
26. Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
27. Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions.
28. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
29. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
30. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies
31. Oral Delivery of the Vancomycin Derivative FU002 by a Surface‐Modified Liposomal Nanocarrier
32. Immunohistochemical FAP Expression Reflects68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
33. Development of Novel Radiopharmaceuticals: Problems, Decisions and More Problems
34. Internal Radiation Therapy
35. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
36. Ligand engineering for theranostic applications
37. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation
38. The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging
39. Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients
40. Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68Ga-FAPI PET/CT
41. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
42. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
43. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors
44. Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery
45. 225Ac-PSMA-617 for Therapy of Prostate Cancer
46. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer
47. Improved pharmacokinetics and enhanced efficacy of the vancomycin derivative FU002 using a liposomal nanocarrier
48. Next Generation of Radiopharmaceuticals via Engineering Antibody Derivatives
49. Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
50. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.